Press Releases

Press Releases

These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools.

Oct 20, 2018
- Patients treated with Agenus' PD-1 & CTLA-4 antibodies show durable clinical benefit 1  in early analyses LEXINGTON, Mass., Oct. 20 ,  2018 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell
Sep 21, 2018
LEXINGTON, Mass., Sept. 21, 2018 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , today announced the closing of its non-dilutive royalty transaction with XOMA Corporation
Sep 17, 2018
- Payment of $5M received for initiation of Phase 1 trial of LAG-3 antibody - Eligible for up to an additional $505 million for milestones plus royalties on sales LEXINGTON, Mass., Sept. 17, 2018 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of
Aug 15, 2018
- Payment of $4M received for initiation of phase 1 trial - Up to additional $95 million for milestones plus royalties on sales LEXINGTON, Mass., Aug. 15, 2018 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer
Jul 16, 2018
-- Sunil Gupta, MD, named Vice President Regulatory & Pharmacovigilance -- Anna Wijatyk, MD, named Vice President Clinical Development LEXINGTON, Mass., July 16, 2018 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with clinical stage checkpoint antibodies, a pipeline of
Jun 20, 2018
LEXINGTON, Mass., June 20, 2018 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1  invites investors and the general public to attend its Annual Meeting of Stockholders to begin
May 17, 2018
- AGEN1884 (CTLA-4) and AGEN2034 (PD-1) show objective clinical responses - More than 100 patients treated with AGEN1884 and AGEN2034 - Combination trial has commenced in cervical cancer LEXINGTON, Mass., May 17 ,  2018 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a
Mar 29, 2018
LEXINGTON, Mass., March 29, 2018 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immune-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, announced today that members of the Company's leadership will present and host one-on-one meetings at two healthcare